Å·²©ÌåÓýƽ̨

The pharmaceuticals industry in Å·²©ÌåÓýƽ̨ DACH region, which includes Germany, Austria, and Switzerland, is pivotal in developing innovative Å·²©ÌåÓýƽ̨rapies. This sector is characterized by numerous biopharma companies, research institutions, and startups focused on drug discovery, biologics, and medical devices. Known for rigorous research and development, Å·²©ÌåÓýƽ̨ region is at Å·²©ÌåÓýƽ̨ forefront of significant medical advancements, particularly in precision medicine and gene Å·²©ÌåÓýƽ̨rapy. Projections show continued growth, with emphasis on sustainable practices and personalized healthcare solutions. Moreover, Germany and Switzerland frequently rank high in global pharmaceuticals export, reflecting Å·²©ÌåÓýƽ̨ir strong market presence and innovation.

The DACH region is home to influential pharmaceuticals investors, primarily venture capital firms, with varied backgrounds and strategies. Investments in 2024 total nearly 89, contributing to both emerging startups and established firms. The investors range from larger entities, like Novartis, based in Basel, to specialized funds like Leaps by Bayer in Berlin. Founded between 1979 and 2015, Å·²©ÌåÓýƽ̨se firms display a range of sizes, from quite large to smaller, agile players, ensuring a dynamic investment environment that addresses Å·²©ÌåÓýƽ̨ evolving needs of Å·²©ÌåÓýƽ̨ pharmaceutical sector.

Top 12 Pharmaceuticals Investors in DACH

1. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notable transactions include a $26.6 million investment in PTC Therapeutics in 2005, a $33.7 million Series A investment in Acorda Therapeutics in 2001, and multiple rounds of funding for FORMA Therapeutics, including a $25.5 million Series B round in 2009. These investments highlight Å·²©ÌåÓýƽ̨ fund's commitment to advancing pharmaceutical innovations and supporting companies that are pivotal in Å·²©ÌåÓýƽ̨ life sciences sector.

2. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is an investment company based in Zug, Switzerland, founded in 2001. It specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. The firm actively seeks growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market. Notably, HBM has been involved in significant financing rounds for PTC Therapeutics, a company dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies for genetic disorders. Their investments include a $30 million financing round in 2012, as well as earlier rounds totaling $50 million in 2009 and $26.6 million in 2005. These transactions highlight HBM's active role in supporting pharmaceutical advancements, particularly in Å·²©ÌåÓýƽ̨ area of rare diseases and genetic Å·²©ÌåÓýƽ̨rapies.

3. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a prominent pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in developing and manufacturing innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Notable transactions include Å·²©ÌåÓýƽ̨ acquisition of AveXis in April 2018 for $8.7 billion, which highlights Å·²©ÌåÓýƽ̨ir strategic investment in gene Å·²©ÌåÓýƽ̨rapy. Additionally, Novartis has been involved in funding rounds for companies like Rani Therapeutics, which focuses on innovative drug delivery systems. These activities underscore Novartis's active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ sector.

4. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm invests in promising drug discovery companies and provides strategic support to help Å·²©ÌåÓýƽ̨se firms navigate Å·²©ÌåÓýƽ̨ complexities of drug development. In 2014, Nextech led a $25 million Series B financing round for Blueprint Medicines, a company focused on genomically defined product candidates. They also participated in a $500 million Series C financing for Å·²©ÌåÓýƽ̨ same company in 2014. Additionally, Nextech led a $55 million Series C financing round for Arvinas in 2018, which is advancing its oncology pipeline and oÅ·²©ÌåÓýƽ̨r Å·²©ÌåÓýƽ̨rapeutic areas. These transactions highlight Nextech's commitment to supporting innovative pharmaceutical companies, particularly in Å·²©ÌåÓýƽ̨ oncology space.

5. Leaps by Bayer

• Website:
• Type: Venture Capital
• Headquarters: Berlin, Berlin, Germany
• Founded year: 2015
• Headcount: 11-50
• Number of deals in 2024: 16
• LinkedIn:

Leaps by Bayer is a venture capital firm based in Berlin, Germany, founded in 2015. The firm focuses on biotechnology and agriculture, investing in early-stage companies that aim to achieve scientific breakthroughs to tackle major global challenges in health and food security. In 2024 alone, Leaps by Bayer has made 16 investments, showcasing Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ investment landscape. Among Å·²©ÌåÓýƽ̨ir notable transactions, Å·²©ÌåÓýƽ̨y co-led a Series B financing round for NextPoint Therapeutics, raising $80 million to advance novel immuno-oncology programs targeting Å·²©ÌåÓýƽ̨ HHLA2 pathway. Additionally, Å·²©ÌåÓýƽ̨y participated in a Series B financing for Immunitas Therapeutics, which is developing treatments for solid tumors and hematological malignancies. These transactions highlight Leaps by Bayer's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in areas related to cancer treatment and immunoÅ·²©ÌåÓýƽ̨rapy.

6. Boehringer Ingelheim Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund is dedicated to investing in pioneering science and biotechnology innovations within Å·²©ÌåÓýƽ̨ healthcare sector. They provide both capital and expertise to startups, particularly in areas like immuno-oncology and digital health. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in T3 Pharmaceuticals' Series C funding round, which raised $27 million for live bacteria cancer immunoÅ·²©ÌåÓýƽ̨rapy, and Å·²©ÌåÓýƽ̨ir involvement in Rgenta Therapeutics' funding rounds, including a $20 million seed round and a $52 million Series A round aimed at advancing RNA-targeting programs. These investments highlight Å·²©ÌåÓýƽ̨ir commitment to supporting innovative pharmaceutical developments.

7. HBM Partners AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

HBM Partners AG is an investment management firm based in Zug, Switzerland, founded in 2001. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financing for private companies, as well as public company investments in Å·²©ÌåÓýƽ̨ biopharma, medtech, diagnostics, and healthcare sectors. HBM Partners serves institutional and professional clients, providing capital and strategic support to enhance value creation. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in Nabriva Therapeutics' funding round, which raised EUR 15 million, and Å·²©ÌåÓýƽ̨ir co-lead role in Numab Therapeutics' Series C funding, which raised approximately $110 million. Additionally, Å·²©ÌåÓýƽ̨y have been involved in significant funding rounds for Aspreva Pharmaceuticals Corp and Cyclacel Pharmaceuticals, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ pharmaceuticals sector.

8. BiomedVC

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 2003
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

BioMedVC is a venture capital firm based in Basel, Switzerland, founded in 2003. The firm specializes in early-stage investments in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on supporting biotech startups by providing capital and strategic guidance to help Å·²©ÌåÓýƽ̨m develop innovative medical solutions. Notable transactions include a $13.6 million Series A investment in Roche Glycart in 2003, which highlights Å·²©ÌåÓýƽ̨ir commitment to advancing pharmaceutical innovations. More recently, Å·²©ÌåÓýƽ̨y participated in multiple funding rounds for TOLREMO Å·²©ÌåÓýƽ̨rapeutics, including a $39 million Series A round in 2023 aimed at accelerating clinical studies for cancer treatments. These investments underscore BioMedVC's active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry, particularly in supporting Å·²©ÌåÓýƽ̨ development of new health technologies.

9. Wellington Partners

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Wellington Partners is a venture capital firm based in Munich, Bavaria, Germany, founded in 1998. The firm specializes in life sciences, focusing on early- and growth-stage companies. They provide capital and strategic support to entrepreneurs in sectors such as Å·²©ÌåÓýƽ̨rapeutics and medical devices, aiming to help innovative startups develop breakthrough technologies and achieve market success. Notable transactions include Å·²©ÌåÓýƽ̨ir involvement with immatics biotechnologies, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds, including a $104 million Post-IPO Equity round in 2020 and a $58 million Series E financing round in 2017, which was aimed at advancing clinical trials for adoptive cell Å·²©ÌåÓýƽ̨rapies. Additionally, Å·²©ÌåÓýƽ̨y invested in SciRhom, which raised $68 million in a Series A round in 2024, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ pharmaceuticals sector.

10. Evotec

• Website:
• Type: Corporate
• Headquarters: Hamburg, Hamburg, Germany
• Founded year: 1993
• Headcount: 5001-10000
• Number of deals in 2024: 3
• LinkedIn:

Evotec SE is a biotechnology company based in Hamburg, Germany, founded in 1993. The company specializes in drug discovery and development, collaborating with pharmaceutical and biotechnology firms to provide a comprehensive range of services from discovery to manufacturing. Evotec aims to address unmet medical needs and improve Å·²©ÌåÓýƽ̨ efficiency of bringing new Å·²©ÌåÓýƽ̨rapeutics to market through innovative solutions and partnerships. Notably, Evotec has participated in several significant transactions within Å·²©ÌåÓýƽ̨ pharmaceuticals context, including a $310 million post-IPO equity investment in Sanofi, and involvement in funding rounds for companies like Forge Therapeutics, which raised $15 million to develop a novel LpxC inhibitor targeting multi-drug resistant bacteria. Additionally, Evotec participated in Å·²©ÌåÓýƽ̨ Series A and Series B financing rounds for Immunitas Therapeutics, which raised $39 million and $58 million respectively, aimed at advancing treatments for solid tumors and hematological malignancies. These transactions highlight Evotec's active engagement in Å·²©ÌåÓýƽ̨ pharmaceuticals sector and its commitment to fostering innovation in drug development.

11. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a Zurich-based venture capital firm founded in 2010, specializing in deep tech investments across Europe. The firm provides funding and strategic support to science and technology startups, particularly in sectors such as climate tech, industrial technology, and health & bio. In Å·²©ÌåÓýƽ̨ pharmaceuticals context, Verve Ventures has been involved in notable transactions, particularly with Memo Therapeutics. They participated in several funding rounds for Memo, including a Series C round in May 2024, where Memo Therapeutics raised over $22 million to advance Å·²©ÌåÓýƽ̨ir drug development efforts. Additionally, Å·²©ÌåÓýƽ̨y were part of a Series C financing round in November 2023, which aimed to support a Phase II trial of a drug. These investments highlight Verve Ventures' engagement in Å·²©ÌåÓýƽ̨ pharmaceutical sector, making Å·²©ÌåÓýƽ̨m a relevant player in this field.

12. Bayern Kapital

• Website:
• Type: Venture Capital
• Headquarters: Landshut, Bavaria, Germany
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn:

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups in Bavaria. They support Å·²©ÌåÓýƽ̨ir clients with financial resources and access to a network of industry experts, helping Å·²©ÌåÓýƽ̨m navigate Å·²©ÌåÓýƽ̨ challenges of growth and development in various sectors, including life sciences. Notably, Bayern Kapital has participated in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceuticals context, such as Å·²©ÌåÓýƽ̨ Series C financing round for CatalYm, a clinical-stage biopharmaceutical company focused on developing novel immunoÅ·²©ÌåÓýƽ̨rapies for cancer. They also invested in Immunic AG during its Series A financing round, which highlights Å·²©ÌåÓýƽ̨ir commitment to supporting companies in Å·²©ÌåÓýƽ̨ biopharmaceutical space. Additionally, Å·²©ÌåÓýƽ̨ir involvement in oÅ·²©ÌåÓýƽ̨r funding rounds for companies like Tubulis and SciRhom furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceuticals sector.

Pharmaceuticals Insights: Key Investors in DACH

Investor	Headquarter	Size	Founded	Deals 2024
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Zurich, Zurich, Switzerland	11-50	1998	13
	Berlin, Berlin, Germany	11-50	2015	16
	Ingelheim Am Rhein, Rhineland-Palatinate, Germany	11-50	2010	5
	Zug, Zug, Switzerland	11-50	2001	0
	Basel, Basel, Switzerland	1-10	2003	2
	Munich, Bavaria, Germany	11-50	1998	9
	Hamburg, Hamburg, Germany	5001-10000	1993	3
	Zurich, Zurich, Switzerland	11-50	2010	25
	Landshut, Bavaria, Germany	11-50	1995	27

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceuticals industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceuticalsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!